Fresenius Medical Care ( (FMS) ) has released its Q4 earnings. Here is a breakdown of the information Fresenius Medical Care presented to its investors.
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases, operating a vast network of dialysis clinics globally and offering a comprehensive range of dialysis products. The company is listed on the Frankfurt and New York Stock Exchanges.
In its latest earnings report, Fresenius Medical Care announced an 18% growth in operating income for 2024, reaching the top end of its forecasted range. The company also reported a 4% organic revenue growth, driven by its Care Enablement and Care Delivery segments, and a significant reduction in its net financial leverage ratio.
Key financial highlights include a reported net income increase of 8% and an impressive 21% planned dividend raise. The FME25 transformation program has already achieved EUR 567 million in savings, prompting an increase in the 2025 savings target to EUR 750 million. The company also saw a positive shift in U.S. market treatment growth and strong performance in Care Enablement.
Looking ahead, Fresenius Medical Care anticipates continued earnings growth in 2025, with expectations of high-teens to high-twenties percent growth in operating income. The company remains focused on executing its strategic plan and optimizing its portfolio to enhance operational efficiency and profitability.